Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib in advanced non-squamous NSCLC
NCT01287962Phase 3Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2011
- Primary completion
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Rivoceranib in non-small cell lung cancer (NSCLC), sponsored by Sun Yat-sen University. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01287962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01287962.